Drug Approval | May 14, 2025
Briefs: Zydus and CuraTeQ Biologics
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration
EBITDA before special items decreases to €4.08 billion (7.4%)
Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy
Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
Investment demonstrates confidence in America’s commitment to science and innovation
Delivers robust earnings performance, successfully navigating a dynamic environment
Subscribe To Our Newsletter & Stay Updated
